Safety and viral load changes in HIV-1 infected subjects treated with autologous dendritic cell immune therapy following ART discontinuation
|
|
|
- Ezra Allen
- 5 years ago
- Views:
Transcription
1 Safety and viral load changes in HIV-1 infected subjects treated with autologous dendritic cell immune therapy following ART discontinuation (CTN #239) Jean-Pierre Routy M.D. McGill University Paris 21 octobre, 29 1
2 Treatment strategy with DC therapy ART STI Pre-ART set point Set point Viral load Time ART STI Pre-ART set point Viral load DC Immunotherapy Set point Time 2
3 Results of DC immunotherapy trials in HIV infection Maturat. HIV Ag Route patients Imm.resp Vir resp Authors None Gp 16, Gag, pol IV 6 3 Kundu 1999 IL-1, IL-6, TNFα Monocyt. condition Auto HIV SC (8%) Lu 24 Auto HIV SC 12 Garcia 25 TNFα IL-1, IL-6, TNF α Gag, Env, Nef Gag, Env, Nef SC 7 2 Ide 26 IV, SC No STI Connoly 28 3
4 Improving HIV DC immunotherapy Limited activity in DC immunotherapy may be explained by: HIV diversity Insufficient co-stimulation and immune potency To overcome these issues: Use autologous vs. consensus antigens CD4L mrna transfection into DC to enhance CD8 response without CD4 help DC administration while patients on ART DC short-lived: Repeat dosing to maintain response 4
5 Results from Phase 1 DC immunotherapy trial (n=1) Manufactured at Argos Therapeutics Durham, NC, USA DC transfected with amplified autologous HIV Gag, Nef, Rev,Vpr RNAs (Vpr modified) Perfectly matched to each patient s unique viral antigens Safe and well tolerated Induce CTL response without need for CD4 help 5
6 Phase 1 immunomonitoring results Difference in Frequency of CD8 and CD4 T Cell Proliferation Pre and Post DC Treatment CD8 CD4 6 Routy et al. In press J Clinical Immunol
7 Study objectives Safety and tolerability Mean time to VL rebound and peak after STI Mean time to best VL response after STI Change in VL after a 12-week STI: Proportion of subjects with CD4 > 35 and: VL < 1 at 3 time points VL < 1 at 3 time points Change in VL compared to pre-art 7
8 Eligibility criteria At screening visit: First ART regimen for > 12 weeks VL < 5 copies/ml for 12 weeks Pre-ART plasma: Availability of 1.2 ml VL > 15 copies/ml CD4 > 45 cell/μl CD4 nadir > 2 cell/μl No co-infection or autoimmunity 8
9 Study Design HIV DC immunotherapy Phase 2a N=24 1 clinical centers AGS-4 DC dosing every 4 weeks 8 weeks 12 weeks ART STI STI & Booster Phase 12 weeks If VL< 1 /ml and CD4> 35 9
10 Patient characteristics (n=24) Total (N = 24) N 24 Mean Age 4.5 Male 24 (1%) White 23 (95.8%) First nation Canadian 1 (4.2%) 1
11 Treatment emergent AEs Treatment Emergent Adverse Event Total (N = 24) Subjects with Treatment Emergent AE grade 3 Subjects with Treatment Emergent AE grade <3 Gastrointestinal symptoms Diarrhea Other Constitutional and administrative site symptoms Fatigue Influenza like illness Injection site erythema Injection site induration Injection site pain Clinical laboratory changes Rheumatoid factor > 2 Neurological symptoms Headache Other No HIV-related events observed
12 Viral load dynamics at 12 weeks post STI (n=16) Mean time to: Weeks Viral rebound (>5) 4.5 Peak VL 7.9 VL and CD4 Changes Mean Change of VL from pre ART 1.13Log ( 8%) (N=13 responders) Mean CD4 at screening 663 ( ) Best VL response (13/16 with reduced VL) 1.1* Mean CD4 at STI start 644 ( ) CD4 at 12 weeks of STI 521 ( ) *4 weeks after last dose; Consistent with requirement for continued monthly dosing in the presence of viremia 12
13 Changes in VL after 12 weeks of STI ** *.3 * * * * * * *Protective HLA allele (B27, B57, or B51) *Susceptibility HLA allele (B45 or B35) 13 ΔLOG (Pre-ART compared to 12 Weeks of STI)
14 Patient 11-5: boosting strategy 12 weeks ART 38 weeks ART 5 45 Pre-ART VL CD4 Counts Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 (Int) Wk16 (Dose) Wk18 Wk2 (Dose) Wk22 Wk24 Wk26 Wk28 (Dose) Wk3 Wk32 Wk34 Wk36 Wk38 Wk4 (Dose) Wk42 Wk44 Wk46 Wk48 Wk5 Wk52 Wk54 Wk56 Wk58 Wk6 Wk62 Wk64 Viral Load (Copies/mL) CD4 nadir = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS , , 32 31, 44 14
15 Patient 11-2: VL rebound 12 weeks ART ART 16 weeks Pre-ART VL Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 (Int) Wk16 (Dose) Wk18 Wk2 (Dose) Wk22 Wk24 Wk26 Wk28 (Dose) Wk3 Wk32 Wk34 Wk36 Wk38 Wk4 Wk42 Wk44 Wk46 Wk48 Wk5 Wk52 Wk64 CD4 Count Viral Load (Copies/mL) CD4 nadir = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS O111, 111 O81,3511 6,6 O4171 O53,63 131,14BCAD 15
16 Patient 11-8: CD4 T cells decrease 12 weeks ART 16 weeks ART 2 Pre-ART VL CD4 Counts Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 Wk16 Wk17 (Int) Wk19 (Dose) Wk21 Wk24 (Dose) Wk26 Wk27 Wk28 Wk29 Wk32 Wk33 Wk35 Wk37 Wk39 Wk41 Wk43 Wk45 Wk47 Wk49 Wk51 Wk53 Wk55 Viral Load (Copies/mL) CD4 nadir = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS , , , 6 32,
17 Patient 22-2: 12 weeks 1 14 ART 22+ weeks Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 (Int) Wk16 (Dose) Wk18 Wk2 (Dose) Wk22 Wk24 Wk26 Wk28 (Retest) Wk3 (Retest) Wk32 (Dose) Wk34 Wk36 CD4 Count Viral Load (Copies/mL) CD4 nadir Pre-ART VL = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS , , 41 6,6 34, , 44 17
18 Patient 11-9: 12 weeks 8 ART 42 weeks Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 (Int) Wk16 (Dose) Wk18 Wk2 (Dose) Wk22 Wk24 Wk26 Wk28 (Dose) Wk3 Wk32 Wk34 Wk36 Wk38 Wk4 (Dose) Wk42 Wk44 Wk46 Wk48 Wk5 Wk52 Wk54 Wk56 CD4 Count Viral Load (Copies/mL) CD4 nadir Pre-ART VL = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS , , , 6 32, , 31 71,
19 Patient 11-11: 12 weeks 9 ART ART weeks 16+ weeks 8 7 Pre-ART VL Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 (Int) Wk16 (Dose) Wk18 Wk21 (Dose) Wk23 Wk24 Wk26 Wk29 (Dose) Wk32 Wk34 Wk36 Wk38 Wk4 (ART Wk42 (ART Wk44 Wk45 Wk48 Wk5 Wk52 Wk54 Wk56 Wk58 CD4 Count Viral Load (Copies/mL) CD4 nadir = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS , 21 81, 353 6, 6 41, 71 21, 31 31,
20 Patient 23-2: 12 weeks 8 ART 2+ weeks 14 7 Pre-ART VL Wk (Dose) Wk2 Wk4 (Dose) Wk6 Wk8 (Dose) Wk1 Wk12 (Dose) Wk14 (Int) Wk16 (Dose) Wk18 Wk2 (Dose) Wk22 Wk24 Wk26 Wk28 (Dose) Wk3 Wk32 Wk34 CD4 Count Viral Load (Copies/mL) CD4 nadir = 1 7 DC administered i.d. Patient ID HLA-A HLA-B HLA-Bw HLA-Cw DQB1 DRB1 AGS , , 443 4, 6 51, , 22 31, 71 2
21 Conclusions DC immunotherapy is safe and well tolerated during both ART and STI Demonstrated feasibility in multicenter setting During 12-week STI: 5/16 subjects had VL < 1 at 3 time points 9/16 subjects had VL <1 at 3 time points Need to optimize DC dosing frequency Based on these interim data we are planning a phase 2b randomized placebo-controlled multicenter clinical trial 21
22 Acknowledgements Université de Montréal Yassine-Diab B Yegorov O Sekaly RP McGill University Boulassel MR Clinical investigators: Jacobson J Angel J Baril JG Gill J Loutfy M Raclis A Smaill F Tremblay C Vezina S Walmsley S National Immune Monitoring Laboratory (NIML), Montréal: Landry C Coutsinos Z Gagnon D Caroline Benoît-Hébert Argos Therapeutics, Durham, NC Healey D Tcherepanova I Chew T Jain R Nicolette C This study has been funded by NIAID, NIH, (No NO1-A1-619), CANVAC-1C and CTN-CIHR #239 and Argos Therapeutics 22
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
How HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
Supporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
MID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
HIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
Human leukocyte antigen (HLA) system
Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN and anti-ctla4 blocking antibodies in melanoma? Helen Gogas, M.D. Ass. Professor in Medical Oncology 1st Department of Medicine,
Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
Management of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection
Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection Mohamed El-Far, PhD CHUM research center (CRCHUM) University of Montreal, QC Canada 6th International Workshop on HIV
08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
Combinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
Epitope Specific CD8 + T Cell Responses Predict Spontaneous Control of HIV Replication
Epitope Specific CD8 + T Cell Responses Predict Spontaneous Control of HIV Replication Florencia Pereyra, MD Partners AIDS Research Center Harvard Medical School Boston, MA Background HIV -1 elicits HLA
ID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
System Biology analysis of innate and adaptive immune responses during HIV infection
System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,
Lower Immune Response in HIV- Positive Girls to the Quadrivalent Human Papillomavirus Vaccine
Lower Immune Response in HIV- Positive Girls to the Quadrivalent Human Papillomavirus Vaccine July 17-18, 2015 7 th International Workshop on HIV Pediatrics Vancouver, Canada J. Brophy, A. Bitnun, J. Raboud,
Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
HIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration
V ALVAC HIV and AIDSVAX B/E Prime Boost HIV 1 Preventive Vaccine Regimen Final Results of the Phase III Community based Trial in Thailand Supachai Rerks Ngarm, Punnee Pittisutthithum, Sorachai Nitayaphan,
DISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
Understanding contraceptive choices among a cohort of HIV-positive women
Understanding contraceptive choices among a cohort of HIV-positive women Malika Sharma, MD FRCPC with Blitz S, Walmsley S, Raboud J, Money D for the CTN 236 investigators January 13, 2014 Conflict of Interest
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Your logo Natural control of HIV infection is associated with an isotype switched IgG antibody response to HIV Gag antigens in patients with
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
HIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
Canadian Immunization Conference 2018 Dec 4
Enveloped Virus-Like Particle (evlp) Cytomegalovirus (CMV) Vaccine is immunogenic and safe: preliminary results of a First-in-Humans Canadian Immunization Network (CIRN) Clinical Trials Network (CTN) -
GlaxoSmithKline, London, United Kingdom; 11 ViiV Healthcare, London, United Kingdom
Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks J Lake, 1 B Trottier, 2 J Garcia-Diaz, 3 H Edelstein,
RAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
DRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
Introduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
Faculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
Low-Level Viremia in HIV
Mountain West AIDS Education and Training Center Low-Level Viremia in HIV Brian R. Wood, MD Medical Director, Mountain West AETC ECHO Telehealth Program Assistant Professor of Medicine, University of Washington
ABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Supporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
RNA Interference: A New Tool in the Toolbox for Treatment of HBV. Discovery On Target Senior Director, Research 25 September 2017
RNA Interference: A New Tool in the Toolbox for Treatment of HBV Amy Lee Discovery On Target Senior Director, Research 25 September 2017 Arbutus Biopharma Boston, MA NASDAQ: ABUS www.arbutusbio.com Chronic
Therapy of Acute HIV-1 Infection: An Update. Susan Little, M.D. Associate Professor of Medicine University of California, San Diego
Therapy of Acute HIV-1 Infection: An Update Susan Little, M.D. Associate Professor of Medicine University of California, San Diego Acute Infection: Treatment Issues Can ARV treatment restore the massive
Innovative diagnostics for HIV, HBV and HCV
Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
Supporting Information
Supporting Information Honegger et al. /pnas.0 HCV proteins Core E E P NS NS NSA NSB NSA NSB HCV peptide pools 9 Fig. S. HCV proteins represented in the nine peptide pool arrays used for the IFN-γ ELISpot
Intermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Intermittent Antiretroviral Therapy (ART) Can Induce Reduction of Viral Rebounding During ART-Interruption Joseph L. Yozviak DO,
Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
Higher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
Evaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment
Evaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment Tariro D Chawana MBChB (UZ), MSc Clinical Pharmacology (UZ), DPhil student None Conflict of interest
HIV Diagnosis and Pathogenesis. HIV-1 Virion
HIV Diagnosis and Pathogenesis Scott M. Hammer, M.D. HIV1 Virion Life Cycle of HIV HIV1 virion HIV1 Virus virion envelope Cell CD4membrane receptor VIRUS BINDING AND ENTRY RELEASE OF PROGENY VIRUS REVERSE
Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins
Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji
RNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
Fostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2012 September 1; 61(1): 19 22. doi:10.1097/qai.0b013e318264460f. Evaluation of HIV-1 Ambiguous Nucleotide
Women with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada
Women with a history of injection drug use at greatest risk for poorer clinical outcomes in a cohort of HIV-positive individuals in Canada Angela Cescon, Alexis K Palmer, Keith Chan, Shari Margolese, Janet
BHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
HIV Immunopathogenesis. Modeling the Immune System May 2, 2007
HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Association of HLA-DRB1-restricted CD4 + T cell responses with HIV immune control Srinika Ranasinghe 1, Sam Cutler 1, Isaiah Davis 1, Richard Lu 2, Damien Z. Soghoian 1, Ying
Pediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
Clinical Case. Prof.ssa Cristina Mussini
Clinical Case Prof.ssa Cristina Mussini Clinical history Male, born in Ivory Coast in 1968. HIV positive since dal 1998 Risk factor: heterosexual contacts He started antiretroviral therapy in 2001 with
Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich DT, Branch AD
On-treatment and Sustained Virologic Response Rates of Telaprevir-based HCV Treatments Do Not Differ Between HIV/HCV Co-infected and HCV Mono-infected Patients Martel-Laferrière V, Brinkley S, Bichoupan
Treatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
Human Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
Frequency and Dynamics of Transmitted Polymorphisms and their Impact on Early Pathogenesis in Heterosexual Couples in Zambia
Frequency and Dynamics of Transmitted Polymorphisms and their Impact on Early Pathogenesis in Heterosexual Couples in Zambia 8 th International Workshop on HIV Transmission Principles of Intervention Barcelona,
Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
Dr Anna Herasimtschuk
19 th Annual Conference of the British HIV Association (BHIVA) Dr Anna Herasimtschuk Imperial College London 16-19 April 213, Manchester Central Convention Complex Therapeutic immunisation in conjunction
Dr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA)
19 th Annual Conference of the British HIV Association (BHIVA) Dr Manisha Yapa Chelsea and Westminster Hospital, London 16-19 April 2013, Manchester Central Convention Complex The impact of switching to
Potential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
MID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. 1 Virion Entry Life Cycle of Entry 1 virion 1 Virus virion envelope Cell CD4membrane receptor RELEASE OF PROGENY VIRUS REVERSE Coreceptor TRANSCRIPTION
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
Immunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
HIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
Human Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
Oncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir
Oncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir Costiniuk CT, Côté SC, Al-Ghazawi FM, Carrasco-Medina L,Young CD, & Angel JB University of Ottawa, November 12 th, 2012 HIV Reservoirs
Diagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia
Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia Dr Bonaventura Clotet Transparency declaration I have served during the past 2 years as
Prescribing Information can be found at the end of the presentation
Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks Prescribing Information can be found at the end
Future trends of drug resistance and prospects of antiviral therapy. Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018
Future trends of drug resistance and prospects of antiviral therapy Doug Richman International Drug Resistance Workshop Johannesburg 24 October 2018 The principles of HIV drug resistance are well established
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
HIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
Laboratory diagnostics CH/HIV/0052/17/10/2017
Laboratory diagnostics CH/HIV/0052/17/10/2017 This slide set was created by ViiV Healthcare GmbH with great care in order to provide balanced information about ViiV products and / or application areas.
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
AIDS free generation. Bob Colebunders Institute of Tropical Medicine
AIDS free generation Bob Colebunders Institute of Tropical Medicine Why this optimism? Rapid scale-up of antiretroviral therapy Treatment can prevent new infections Expanded coverage of programmes to prevent
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
Second and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
Parallel session IVB. Chair: Hans Wildiers
Parallel session IVB Biology of ageing and cancer Chair: Hans Wildiers IMMUNOSENESCENCE AND AGEING Tamas Fulop M.D., PhD Research Center on Aging, Division of Geriatrics, University of Sherbrooke, Sherbrooke,
The Canadian HIV Cure Enterprise (CanCURE) Team
The Canadian HIV Cure Enterprise (CanCURE) Team Éric A. Cohen, PhD Laboratory of Human Retrovirology Institut de Recherches Cliniques de Montréal (IRCM) How close are we to a cure? HIV Endgame Conference,
Update on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
ICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
What is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
Synopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate